UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
 
Date of Report:   October 27, 2016
(Date of earliest event reported)
 
Invitae Corporation
(Exact name of registrant as specified in its charter)

Delaware	 	001-36847	 	27-1701898	
(State or other jurisdiction of	 	(Commission File Number)	 	(I.R.S. employer	
incorporation or organization)	 	 	 	identification number)	
 
458 Brannan Street, San Francisco, California 94107
(Address of principal executive offices, including zip code)
 
(415) 374-7782
 (Registrant’s telephone number, including area code)
 
N/A
(Former Name or Former Address, if Changed Since Last Report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
o              Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o              Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o              Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
Item 8.01                                            Other Events.
 
Invitae Corporation announced that it entered into a national provider agreement for laboratory services with Humana, effective December 1, 2016.
 
2 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated:  October 27, 2016

 	INVITAE CORPORATION	

 	By:	/s/ Lee Bendekgey	
 	Name:	Lee Bendekgey	
 	Title:	Chief Financial Officer, General Counsel and Secretary	
 
3